1. Home
  2. SG vs ARVN Comparison

SG vs ARVN Comparison

Compare SG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$7.00

Market Cap

640.3M

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$10.13

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
ARVN
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
658.2M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SG
ARVN
Price
$7.00
$10.13
Analyst Decision
Hold
Buy
Analyst Count
15
19
Target Price
$8.43
$15.05
AVG Volume (30 Days)
3.6M
640.4K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
$679,474,000.00
$262,600,000.00
Revenue This Year
$7.60
N/A
Revenue Next Year
$8.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.39
N/A
52 Week Low
$4.49
$5.90
52 Week High
$17.27
$14.22

Technical Indicators

Market Signals
Indicator
SG
ARVN
Relative Strength Index (RSI) 60.42 40.77
Support Level $6.51 $9.96
Resistance Level $7.43 $10.18
Average True Range (ATR) 0.41 0.55
MACD -0.02 0.03
Stochastic Oscillator 57.80 23.95

Price Performance

Historical Comparison
SG
ARVN

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: